AUGMENTIN — Co-amoxiclav (Amoxicillin/Clavulanate) 625 mg, 1g tablets

Augmentin is the brand name for co-amoxiclav, a fixed‑dose combination antibiotic containing amoxicillin (a penicillin‑class antibiotic) and clavulanate potassium (a beta‑lactamase inhibitor). It was first approved in the US in 1984 and remains one of the most widely prescribed broad‑spectrum antibiotics worldwide. The combination is designed to overcome bacterial resistance mediated by beta‑lactamase enzymes.

Mechanism of action: Amoxicillin kills bacteria by inhibiting the synthesis of bacterial cell walls, leading to cell lysis. However, some bacteria produce beta‑lactamase enzymes that inactivate amoxicillin by breaking open its beta‑lactam ring. Clavulanate has weak antibacterial activity itself but irreversibly binds to beta‑lactamases, protecting amoxicillin from degradation. This extends amoxicillin‘s spectrum to include beta‑lactamase‑producing strains of Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Escherichia coli, Klebsiella species, and others.

Clinical indications: Augmentin is indicated for a wide range of community‑acquired infections in adults and children, including lower respiratory tract infections (e.g., community‑acquired pneumonia, bronchitis), acute bacterial otitis media, sinusitis, skin and skin structure infections (e.g., cellulitis, abscesses, wound infections), urinary tract infections, dental abscesses, and bone/joint infections (e.g., osteomyelitis). It is also used for surgical prophylaxis in certain procedures.

Limitations of use: When susceptibility testing shows that the infecting bacteria are susceptible to amoxicillin alone (i.e., they do not produce beta‑lactamase), Augmentin should not be used, as the clavulanate component adds unnecessary risk of hepatotoxicity and gastrointestinal side effects. Augmentin is not effective against viruses (common cold, flu) and should be used only for proven or strongly suspected bacterial infections to reduce the development of drug resistance.

• History of a serious hypersensitivity reaction (e.g., anaphylaxis) to amoxicillin, clavulanate, any penicillin, or other beta‑lactam antibiotics (cephalosporins, carbapenems).
• History of cholestatic jaundice or hepatic dysfunction associated with Augmentin use.
• Known hypersensitivity to any component of the formulation.
• Do not use when amoxicillin alone is effective (i.e., infections caused by bacteria not producing beta‑lactamase).

• Probenecid: Decreases renal tubular secretion of amoxicillin, increasing and prolonging amoxicillin blood levels. Not recommended.
• Oral anticoagulants (warfarin): May increase INR and bleeding risk. Monitor coagulation parameters closely.
• Allopurinol: Concomitant use increases risk of rash.
• Oral contraceptives: Amoxicillin/clavulanate may reduce efficacy of hormonal contraceptives. Advise patients to use additional non‑hormonal contraception (condoms, diaphragm) during treatment and for 7 days after stopping.
• Methotrexate: Penicillins may reduce methotrexate clearance, increasing toxicity risk. Monitor methotrexate levels.
• Mycophenolate mofetil: Amoxicillin/clavulanate may reduce mycophenolic acid concentrations. Monitor for reduced efficacy.
• Tetracyclines, macrolides, chloramphenicol: Bacteriostatic antibiotics may antagonize bactericidal action of penicillins. Avoid concurrent use.

• Pregnancy: Generally considered safe. Animal studies do not indicate direct or indirect harmful effects. Use if clearly needed.
• Breastfeeding: Amoxicillin and clavulanate are excreted in breast milk in small amounts. Considered compatible with breastfeeding; monitor infant for diarrhea, rash, or thrush.
• Pediatric use: Safety established. Dosing based on weight and age. Neonates and infants less than 12 weeks: 30 mg/kg/day divided every 12 hours (based on amoxicillin). Children 12 weeks and older: 25‑45 mg/kg/day every 12 hours or 20‑40 mg/kg/day every 8 hours. Do not exceed adult dose.
• Geriatric use: No specific problems demonstrated, but elderly more likely to have age‑related renal impairment; dose adjustment may be needed. Increased risk of hepatotoxicity.
• Renal impairment: GFR 10‑30 mL/min: 250‑500 mg every 12 hours (based on amoxicillin). GFR less than 10 mL/min: 250‑500 mg every 24 hours. Hemodialysis: 250‑500 mg during dialysis and after. Extended‑release tablets contraindicated in severe renal impairment.
• Hepatic impairment: Use with caution; monitor liver function tests. Contraindicated in history of Augmentin‑associated jaundice/hepatic dysfunction.

• Symptoms: Nausea, vomiting, diarrhea, stomach pain, skin rash, drowsiness, hyperactivity, decreased urination. Crystalluria possible with high doses.
• Management: Supportive care, fluid monitoring, correction of electrolyte imbalances. Activated charcoal may be considered if recent ingestion. Hemodialysis removes amoxicillin/clavulanate.